| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 2,263,580 | 2,354,550 | 2,237,220 | 2,289,460 | 2,122,350 |
| Sales Growth | -3.86% | +5.24% | -2.28% | +7.87% | +16.98% |
| Net Income | 858,980 | 1,134,830 | 42,830 | 619,730 | 975,040 |
| Net Income Growth | -24.31% | +2,549.61% | -93.09% | -36.44% | -58.48% |
Royalty Pharma Plc Cl A (RPRX)
33.59 x 1 33.90 x 1
Post-market by (Cboe BZX)
33.75 +0.05 (+0.15%) 03/24/25 [NASDAQ]
33.59 x 1 33.90 x 1
Post-market 33.75 unch (unch) 16:39 ET
for Mon, Mar 24th, 2025
Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.
Fiscal Year End Date: 12/31